Turret Capital Management announced that it has signed a Definitive License Agreement with Genexine, inc. Under the terms of the agreement, Turret Capital has obtained global rights for selective indications to GX-P1.  GX-P1 is a Phase I ready novel immunosuppressant agent that reduces the immune response by binding to PD-1 on activated T cells and thus inhibiting T cell activation; a mechanism that is opposite to that of an anti-PD-L1 immune checkpoint inhibitor typically used to treat cancer. The compound will be housed and developed within Egret Therapeutics, a subsidiary of Turret Capital, and will target clinical areas of unmet need in the area of acute subarachnoid hemorrhage.